Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
06/30/2025
06/30/2024
06/30/2023
06/30/2022
06/30/2021
Revenus
12
12
11
10
11
18
Croissance des revenus (H/H)
9%
9%
10%
-9%
-39%
260%
Coût des ventes
4
4
4
4
7
10
Bénéfice brut
7
7
7
5
4
8
Vente, Général et Administration
12
12
11
11
26
18
Recherche et développement
0
0
0
0
1
1
Frais d'exploitation
14
14
13
15
28
19
Autres revenus (charges) non opérationnels
--
--
--
--
--
--
Bénéfice avant impôts
-7
-7
-8
-8
-45
-15
Charge d'impôt sur le revenu
0
0
0
0
0
0
Bénéfice net
-7
-7
-8
-8
-45
-15
Croissance du bénéfice net
-13%
-13%
0%
-82%
200%
67%
Actions en circulation (diluées)
747.4
680.18
493.65
250.28
223.7
150.15
Variation des actions (H-H)
46%
38%
97%
12%
49%
-6%
EPS (dilué)
-0.01
-0.01
-0.01
-0.03
-0.2
-0.1
Croissance du EPS
-42%
-39%
-51%
-82%
104%
77%
Flux de trésorerie libre
-9
-9
0
-9
-22
-19
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
58.33%
58.33%
63.63%
50%
36.36%
44.44%
Marge opérationnelle
-50%
-50%
-54.54%
-90%
-209.09%
-55.55%
Marge bénéficiaire
-58.33%
-58.33%
-72.72%
-80%
-409.09%
-83.33%
Marge du flux de trésorerie libre
-75%
-75%
0%
-90%
-200%
-105.55%
EBITDA
-4
-4
-4
-6
--
--
Marge EBITDA
-33.33%
-33.33%
-36.36%
-60%
--
--
D&A pour le résultat opérationnel
2
2
2
3
--
--
EBIT
-6
-6
-6
-9
-23
-10
Marge EBIT
-50%
-50%
-54.54%
-90%
-209.09%
-55.55%
Taux d'imposition effectif
0%
0%
0%
0%
0%
0%
Statistiques clés
Clôture préc.
$0.1692
Prix d'ouverture
$0.17
Plage de la journée
$0.17 - $0.17
Plage de 52 semaines
$0.01 - $0.2105
Volume
35.0K
Volume moyen
49.4K
BPA (TTM)
-0.01
Rendement en dividend
--
Capitalisation boursière
$134.7M
Qu’est-ce que LUMOS DIAGNOSTICS HLDGS LTD ?
Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm offers customized assay development and manufacturing services for POC tests and digital reader platforms. The company also directly develops, manufactures, and commercializes Lumos-branded POC tests that target infectious and inflammatory diseases. Its Products offering is based on developing and commercializing its own suite of POC diagnostic products which are primarily focused on the diagnosis and management of infectious diseases. These include FebriDx, a POC test for detecting and differentiating viral and bacterial respiratory infections, and ViraDx, a rapid point-of-care diagnostic product that simultaneously tests for acute respiratory infections caused by the COVID-19, influenza A, and influenza B viruses. The company manages the full development program for POC assays.